Selection of clinical studies of endothelin receptor antagonists in the field of pulmonary hypertension
| Acronym | Title | Drug | Description | [Ref.] |
| ARIES | Ambrisentan in PAH – a phase III, randomized, double-blind, placebo-controlled, multicenter, efficacy study of ambrisentan in subjects with pulmonary arterial hypertension | Ambrisentan | ||
| ARIES-1 | RPCT of 5 and 10 mg ambrisentan q.d. compared to placebo in PAH patients | 48 | ||
| ARIES-2 | RPCT of 2.5 and 5 mg ambrisentan q.d. compared to placebo in PAH patients | 49 | ||
| BREATHE | Bosentan Randomized Trial of Endothelin Antagonist THErapy | Bosentan | ||
| BREATHE-1 | RCT of bosentan versus placebo in PAH patients | 50 | ||
| BREATHE-2 | RPCT of co-treatment with bosentan or placebo in PAH patients receiving epoprostenol | 51 | ||
| BREATHE-3 | Uncontrolled trial of bosentan in children with PAH | 52 | ||
| BREATHE-4 | Uncontrolled trial of bosentan in HIV-infected patients | 53 | ||
| BREATHE-5 | RPCT of bosentan versus placebo in patients with Eisenmenger physiology | 54 | ||
| EARLY | Endothelin Antagonist tRial in miLdlY symptomatic PAH patients | RPCT of bosentan versus placebo in PAH patients presenting in functional class II | NYP | |
| BENEFiT | Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension | RPCT of bosentan versus placebo in CTEPH patients | NYP | |
| COMPASS-2 | Effects of Combination Of bosentan and sildenafil versus sildenafil Monotherapy on morbidity and mortality in symptomatic PAtientS with PAH-2 | RPCT of bosentan versus placebo as add-on therapy in PAH patients already receiving sildenafil | Ongoing | |
| STRIDE | Sitaxsentan To Relieve ImpaireD Exercise | Sitaxsentan | ||
| STRIDE-1 | RPCT of 100 and 300 mg sitaxsentan q.d. versus placebo in PAH patients | 55 | ||
| STRIDE-2 | RPCT of 50 and 100 mg sitaxsentan q.d. versus placebo in PAH patients | 56 |
RPCT: randomised placebo-controlled trial; PAH: pulmonary arterial hypertension; RCT: randomised controlled trial; CTEPH: chronic thromboembolic pulmonary hypertension; NYP: not yet published.